Ep204: Troy Wilson on Precision Cancer Drugs and Combos

The development of novel cancer therapies requires a long-term commitment to scientific innovation and strategic business execution. Troy Wilson, co-founder and CEO of Kura Oncology, details the company's path from early-stage R&D to the FDA approval of Ziftomenib, a first-in-class menin inhibitor for acute myeloid leukemia. This therapeutic approach shifts the treatment paradigm by inducing cancer cells to differentiate into normal cells rather than relying solely on cytotoxic effects. Beyond this success, Kura is leveraging its expertise in farnesyl transferase inhibitors to address resistance pathways in cancers, particularly when combined with emerging RAS inhibitors like daroxonracib. Wilson emphasizes that building a successful biotech company hinges on fostering a transparent, patient-centric culture and maintaining the agility to pivot toward high-impact, differentiated scientific solutions that address unmet clinical needs.